4//SEC Filing
REINHARDT MAX 4
Accession 0001209191-22-025120
CIK 0001396814other
Filed
Apr 19, 8:00 PM ET
Accepted
Apr 20, 8:25 PM ET
Size
20.7 KB
Accession
0001209191-22-025120
Insider Transaction Report
Form 4
REINHARDT MAX
President
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2022-04-19−12,500→ 125,000 totalExercise: $42.54Exp: 2029-07-02→ Common Stock (12,500 underlying) - Exercise/Conversion
Common Stock
2022-04-19$42.54/sh+12,500$531,750→ 33,559 total - Exercise/Conversion
Common Stock
2022-04-18$42.54/sh+12,500$531,750→ 30,000 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-04-20−12,500→ 112,500 totalExercise: $42.54Exp: 2029-07-02→ Common Stock (12,500 underlying) - Exercise/Conversion
Common Stock
2022-04-20$42.54/sh+12,500$531,750→ 36,738 total - Sale
Common Stock
2022-04-20$73.99/sh−9,764$722,438→ 26,974 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-04-18−12,500→ 137,500 totalExercise: $42.54Exp: 2029-07-02→ Common Stock (12,500 underlying) - Sale
Common Stock
2022-04-19$72.25/sh−9,321$673,442→ 24,238 total - Sale
Common Stock
2022-04-18$73.55/sh−8,941$657,611→ 21,059 total
Footnotes (4)
- [F1]The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
- [F2]Represents shares sold by the reporting person to cover the (i) exercise price of stock options and (ii) tax obligations due upon the exercise of such stock options.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.01 to $72.55, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F4]The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.
Documents
Issuer
Pacira BioSciences, Inc.
CIK 0001396814
Entity typeother
Related Parties
1- filerCIK 0001780058
Filing Metadata
- Form type
- 4
- Filed
- Apr 19, 8:00 PM ET
- Accepted
- Apr 20, 8:25 PM ET
- Size
- 20.7 KB